Animal use in biologics development, production, and testing - - PowerPoint PPT Presentation

▶
animal use in biologics development production and testing
SMART_READER_LITE
LIVE PREVIEW

Animal use in biologics development, production, and testing - - PowerPoint PPT Presentation

Jan 23, 2023 6 likes •366 views

Animal use in biologics development, production, and testing Implementing Nonanimal Approaches to Human and Veterinary Vaccine Testing: Achieving Scientific and Regulatory Success for Rabies and Beyond October 10, 2018 Jeffrey Brown

slide-1
SLIDE 1

Animal use in biologics development, production, and testing

Implementing Nonanimal Approaches to Human and Veterinary Vaccine Testing: Achieving Scientific and Regulatory Success for Rabies and Beyond

October 10, 2018 Jeffrey Brown JeffreyB@PISCLtd.org.uk

slide-2
SLIDE 2

2

PETA International Science Consortium

slide-3
SLIDE 3

3

PETA International Science Consortium

See full list of publications at PISCLtd.org.uk/SciPubs

slide-4
SLIDE 4
  • Progress and problems
  • 3Rs policies for rabies vaccines (etc.)
  • Tracking animal use and 3Rs policy implementation
  • “Peripheral” animal use
  • Progress to come
  • Antibody production
  • Pyrogen testing

4

Outline

slide-5
SLIDE 5

2011 rabies vaccine workshop

5

slide-6
SLIDE 6

2011 rabies vaccine workshop

6

slide-7
SLIDE 7

2011 rabies vaccine workshop: NIH test problems

7

  • ~200 mice per test
  • ~50% experience significant unrelieved pain prior to euthanasia
  • Up to 42% of tests invalid, must be repeated
  • Up to 400% differences in estimated potency

Stokes W, McFarland R, Kulpa-Eddy J, Gatewood D, Levis R, Halder M, Pulle G, Kojima H, Casey W, Gaydamka A, Miller T, Brown K, Lewis C, Capsal JM, Bruckner L, Gairola S, Kamphuis E, Rupprecht CE, Wunderli P, McElhinney L, De Mattia F, Gamoh K, Hill R, Reed D, Doelling V, Johnson N, Allen D, Rinkel L, Jones B. Report on the international workshop on alternative methods for human and veterinary rabies vaccine testing: state of the science and planning the way forward. Biologicals. 2012;40(5):369-381.

slide-8
SLIDE 8

NIH test

8

Bruckner L, Cussler K, Halder M, Barrat J, Castle P, Duchow K, Gatewood DM, Gibert R, Groen J, Knapp B, Levis R, Milne C, Parker S, Stünkel K, Visser N, Volkers P; ECVAM. Three Rs approaches in the quality control of inactivated rabies vaccines. The report and recommendations of ECVAM workshop 48. Altern Lab Anim. 2003; 31(4):429-454.

slide-9
SLIDE 9

NIH test

9

Bruckner L, Cussler K, Halder M, Barrat J, Castle P, Duchow K, Gatewood DM, Gibert R, Groen J, Knapp B, Levis R, Milne C, Parker S, Stünkel K, Visser N, Volkers P; ECVAM. Three Rs approaches in the quality control of inactivated rabies vaccines. The report and recommendations of ECVAM workshop 48. Altern Lab Anim. 2003; 31(4):429-454.

slide-10
SLIDE 10
  • Implementation strategy to:
  • Replace NIH test with ELISA and/or SNT
  • EPAA pre-validation study and EDQM international collaborative

study

  • Reduce numbers of mice used to meet NIH test requirements
  • USDA Center for Veterinary Biologics (CVB) Notice 13-10,

eliminates upper limit LD50 for a valid challenge

  • Reduce pain for mice used in NIH test
  • USDA SAM 308 revised, allows anesthesia for mice prior to virus

injection

  • USDA CVB Notice 12-12, firms encouraged to use anesthesia prior

to virus injection (etc.)

2011 rabies vaccine workshop: Progress

10

Stokes W, McFarlandR, Kulpa-Eddy J, Gatewood D, Levis R, Halder M, Pulle G, Kojima H, Casey W, Gaydamka A, Miller T, Brown K, Lewis C, Capsal JM, Bruckner L, Gairola S, Kamphuis E, Rupprecht CE, Wunderli P, McElhinney L, De Mattia F, Gamoh K, Hill R, Reed D, Doelling V, Johnson N, Allen D, Rinkel L, Jones B. Report on the international workshop on alternative methods for human and veterinary rabies vaccine testing: state of the science and planning the way forward. Biologicals. 2012;40(5):369-381.

slide-11
SLIDE 11
  • Implementation strategy to:
  • Replace NIH test with ELISA and/or SNT
  • EPAA pre-validation study and EDQM international collaborative

study

  • Reduce numbers of mice used to meet NIH test requirements
  • USDA Center for Veterinary Biologics (CVB) Notice 13-10,

eliminates upper limit LD50 for a valid challenge

  • Reduce pain for mice used in NIH test
  • USDA SAM 308 revised, allows anesthesia for mice prior to virus

injection

  • USDA CVB Notice 12-12, firms encouraged to use anesthesia prior

to virus injection (etc.)

2011 rabies vaccine workshop: Progress

11

Stokes W, McFarland R, Kulpa-Eddy J, Gatewood D, Levis R, Halder M, Pulle G, Kojima H, Casey W, Gaydamka A, Miller T, Brown K, Lewis C, Capsal JM, Bruckner L, Gairola S, Kamphuis E, Rupprecht CE, Wunderli P, McElhinney L, De Mattia F, Gamoh K, Hill R, Reed D, Doelling V, Johnson N, Allen D, Rinkel L, Jones B. Report on the international workshop on alternative methods for human and veterinary rabies vaccine testing: state of the science and planning the way forward. Biologicals. 2012;40(5):369-381.

slide-12
SLIDE 12

Problems: counting animals

12

slide-13
SLIDE 13

Problems: counting animals

13

Laboratory Animal Welfare Act of 1966, P.L. 89-544

slide-14
SLIDE 14
  • Required to carry out NIH test
  • Virus propagation: birds, mice, hamsters
  • Required to meet product standard requirements
  • Immunogenicity: target species
  • Purity: mice
  • Safety: mice, rabbits, other species
  • Duration of immunity: target species
  • “Peripheral” animals used in experiments
  • Antibody sources
  • Serum sources
  • Pyrogen testing

Problems: Not just the NIH test

14

slide-15
SLIDE 15

Problems: Animal-derived antibodies

15

Stokes W, McFarland R, Kulpa-Eddy J, Gatewood D, Levis R, Halder M, Pulle G, Kojima H, Casey W, Gaydamka A, Miller T, Brown K, Lewis C, Capsal JM, Bruckner L, Gairola S, Kamphuis E, Rupprecht CE, Wunderli P, McElhinney L, De Mattia F, Gamoh K, Hill R, Reed D, Doelling V, Johnson N, Allen D, Rinkel L, Jones B. Report on the international workshop on alternative methods for human and veterinary rabies vaccine testing: state of the science and planning the way forward. Biologicals. 2012;40(5):369-381.

slide-16
SLIDE 16

Problems: Animal-derived antibodies

16

Groff K, Brown J, Clippinger AJ. Modern affinity reagents: recombinant antibodies and aptamers. Biotechnol Adv. 2015;33(8):1787-1798.

slide-17
SLIDE 17

Problems: Animal-derived antibodies

17

Image: PETA US

slide-18
SLIDE 18

Progress to come: recombinant antibodies

18

  • Phage display
slide-19
SLIDE 19

Progress to come: recombinant antibodies

19

Bradbury A, Plückthun A. Reproducibility: Standardize antibodies used in research. Nature. 2015;518(7537):27-29.

slide-20
SLIDE 20

Progress to come: recombinant antibodies

20

Bradbury A, Plückthun A. Reproducibility: Standardize antibodies used in research. Nature. 2015;518(7537):27-29.

slide-21
SLIDE 21

Progress to come: recombinant antibodies

21

slide-22
SLIDE 22

Progress to come: recombinant antibodies

22

slide-23
SLIDE 23

Animal use: antibody sources

23

Images: USDA Inspection Reports

slide-24
SLIDE 24

Animal use: antibody sources

24

Images: USDA Inspection Reports

slide-25
SLIDE 25

Animal use: antibody sources

25

Images: USDA Inspection Reports

slide-26
SLIDE 26

Animal use: antibody sources

26

Images: USDA Inspection Reports

slide-27
SLIDE 27

Animal use: antibody sources

27

Images: USDA Inspection Reports

slide-28
SLIDE 28

Animal use: antibody sources

28

Images: PETA India

slide-29
SLIDE 29

Animal use: antibody sources

29

Images: PETA India

slide-30
SLIDE 30

Animal use: antibody sources

30

Images: PETA India

slide-31
SLIDE 31

Progress to come: replacing animal antibodies

31

  • Datmab project
  • Phage display, select recombinant human antibodies against

diphtheria toxin

  • Assess toxin neutralization of toxin binding antibodies
  • Convert neutralizing antibodies with best binding affinity to IgG
  • Freeze-dry formulation and stability testing
  • Public health stakeholders, further development
slide-32
SLIDE 32

Progress to come: pyrogen testing

32

Images: Cruelty Free International; Timothy Fadek / Corbis / Getty; The Atlantic

slide-33
SLIDE 33

Progress to come: pyrogen testing

33

Zhang S. The Last Days of the Blue-Blood Harvest. The Atlantic. May 9, 2018.

slide-34
SLIDE 34

Progress to come: pyrogen testing

34

Image: Merck

slide-35
SLIDE 35

Summary

35

  • Success is difficult to quantify
  • How to measure impact of animal replacement,

reduction, refinement policies?

  • NIH test replacement is within reach
  • Improved antibody sources should be prioritised
  • Antibody production → recombinant methods
  • Research, diagnostic, and therapeutic relevance
  • Ensuring use of other available replacements
  • RPT/BET → MAT

Contact: Jeffrey Brown JeffreyB@PISCLtd.org.uk www.PISCLtd.org.uk @PISCLtd